A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

NCT07385001 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma
Ivonescimab
Neoadjuvant

Interventions

DRUG: AK112
DRUG: AK112
DRUG: AK112 + Neoadjuvant chemotherapy

Sponsor

Tang-Du Hospital